Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma

BMC Veterinary Research

Table 1 Patient Characteristics of Dogs Diagnosed with Pancreatic Carcinoma Treated with Toceranib Phosphate

Case Number	Breed	Gender	Diagnosis Via	Toceranib Dose (mg)	Best Response	Imaging used to assess response	Toceranib-specific Survival Time (days)	Cause of Death
1	Golden Retriever	MC	Cytology	2.2	PD	Clinical response	52	Pancreatic Carcinoma
2	Golden Retriever	FS	Cytology/Histopathology	2.8	SD	AUS and CXR every 8–12 weeks	302	Pancreatic Carcinoma
3	Beagle	FS	Histopathology	2.7	*	N/A	LTF: 82	Lost to follow-up
4	Beagle	FS	Histopathology	2.4	*	N/A	14	Pancreatic Carcinoma
5	Shih Tzu	FS	Cytology	2.8	PR	AUS	97	Lost to follow-up
6	Pitbull	MC	Histopathology	2.3	SD	AUS	Alive at Data Capture (05/12/2021): 506	N/A
7	Old English Sheepdog	FS	Cytology	2.2	PD	AUS	17	Unknown
8	Irish Terrier	FS	Histopathology	2.5	SD	Clinical response	301	Pancreatic Carcinoma

AUS Abdominal Ultrasound, CXR Chest radiographs, FS Female spayed, LTF Lost to follow-up, MC male castrated, PD progressive disease, PR partial remission, SD stable disease
*Toceranib used in the microscopic disease setting

ISSN: 1746-6148